Skye Bioscience (SKYE) Non Operating Interest Expenses (2013 - 2026)

Skye Bioscience (SKYE) has reported Non Operating Interest Expenses for 11 consecutive years, with $3299.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses changed N/A year-over-year to $3299.0 in Q2 2026; TTM through Jun 2026 was $5498.0, a 104.04% increase from a year earlier, with the FY2024 full-year figure at $749308.0, down 17.32% from the prior year.
• Non Operating Interest Expenses was $3299.0 for Q2 2026 at Skye Bioscience, up from $2199.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $450052.0 in Q2 2024 and troughed at -$90766.0 in Q3 2024.
• A 5-year average of $155177.1 and a median of $186429.0 in 2023 frame the typical range for Non Operating Interest Expenses.
• The widest YoY moves for Non Operating Interest Expenses: up 2275.17% in 2024, down 133.46% in 2024.
• Over 5 years, Non Operating Interest Expenses stood at $49570.0 in 2022, then jumped by 767.73% to $430135.0 in 2023, then plunged by 110.91% to -$46914.0 in 2024, then surged by 103.1% to $1452.0 in 2025, then surged by 127.2% to $3299.0 in 2026.
• The last three Non Operating Interest Expenses figures came in at $3299.0 (Q2 2026), $2199.0 (Q1 2026), and $1452.0 (Q1 2025), per Business Quant data.